Altamira Therapeutics

Altamira Therapeutics

Pharmaceutical Manufacturing

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets.

About us

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Additionally, the Company is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infections and inner ear therapeutics. The Company was founded in 2003, under the name Auris Medical, and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”

Industry
Pharmaceutical Manufacturing
Company size
11-50 employees
Headquarters
Hamilton
Type
Public Company
Founded
2003

Locations

Employees at Altamira Therapeutics

Updates

Similar pages

Funding

Altamira Therapeutics 6 total rounds

Last Round

Post IPO equity

US$ 4.0M

See more info on crunchbase